Biogen Company Profile (NASDAQ:BIIB)

About Biogen

Biogen logoBiogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; BIIB061; BIIB054; BIIB067, and BIIB068.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BIIB
  • CUSIP: 09062X10
Key Metrics:
  • Previous Close: $287.63
  • 50 Day Moving Average: $281.35
  • 200 Day Moving Average: $296.39
  • 52-Week Range: $223.02 - $333.65
  • Trailing P/E Ratio: 16.85
  • Foreward P/E Ratio: 12.77
  • P/E Growth: 2.18
  • Market Cap: $61.62B
  • Outstanding Shares: 215,951,000
  • Beta: 0.72
  • Net Margins: 32.34%
  • Return on Equity: 38.48%
  • Return on Assets: 20.29%
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 2.55%
  • Quick Ratio: 2.26%
Additional Links:
Companies Related to Biogen:

Analyst Ratings

Consensus Ratings for Biogen (NASDAQ:BIIB) (?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 12 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.59)
Consensus Price Target: $332.53 (15.61% upside)

Analysts' Ratings History for Biogen (NASDAQ:BIIB)
DateFirmActionRatingPrice TargetDetails
2/11/2017Credit Suisse GroupSet Price TargetHold$296.00View Rating Details
2/7/2017Citigroup Inc.UpgradeNeutral -> Buy$305.00View Rating Details
2/7/2017Robert W. BairdReiterated RatingHoldView Rating Details
2/6/2017MizuhoReiterated RatingSellView Rating Details
2/2/2017RBC Capital MarketsReiterated RatingBuyView Rating Details
1/30/2017HC WainwrightReiterated RatingBuy$360.00View Rating Details
1/26/2017Cantor FitzgeraldSet Price TargetHold$293.00View Rating Details
1/27/2017Morgan StanleyBoost Price TargetOverweight$353.00 -> $369.00View Rating Details
1/24/2017BMO Capital MarketsReiterated RatingMarket Perform$336.00View Rating Details
1/24/2017Jefferies Group LLCReiterated RatingHold$313.00View Rating Details
1/18/2017Leerink SwannSet Price TargetBuy$360.00View Rating Details
1/18/2017J P Morgan Chase & CoReiterated RatingBuyView Rating Details
1/17/2017Piper Jaffray CompaniesSet Price TargetBuy$335.00View Rating Details
1/17/2017Stifel NicolausSet Price TargetHold$298.00View Rating Details
12/30/2016Cowen and CompanyReiterated RatingBuy$368.00View Rating Details
12/29/2016Raymond James Financial, Inc.Boost Price TargetStrong-Buy$375.00 -> $386.00View Rating Details
9/22/2016Bank of America CorpReiterated RatingBuy$374.00View Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldView Rating Details
6/29/2016Sanford C. BernsteinInitiated CoverageOutperform$282.00View Rating Details
6/8/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
6/8/2016Wells Fargo & CompanyReiterated RatingBuyView Rating Details
4/23/2016Goldman Sachs Group, Inc. (The)Reiterated RatingHoldView Rating Details
1/27/2016William BlairReiterated RatingOutperformView Rating Details
1/22/2016Barclays PLCReiterated RatingBuy$420.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00View Rating Details
9/23/2015Oppenheimer Holdings, Inc.Reiterated RatingSector PerformView Rating Details
8/11/2015Deutsche Bank AGReiterated RatingBuyView Rating Details
7/27/2015ArgusLower Price TargetBuy$450.00 -> $360.00View Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details
4/27/2015NomuraReiterated RatingNeutral$401.00 -> $442.00View Rating Details
(Data available from 2/23/2015 forward)


Earnings History for Biogen (NASDAQ:BIIB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.77$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.81$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biogen (NASDAQ:BIIB)
Current Year EPS Consensus Estimate: $20.98 EPS
Next Year EPS Consensus Estimate: $22.52 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$3.82$4.71$4.40
Q2 20164$4.41$4.74$4.62
Q3 20164$4.49$5.05$4.79
Q4 20164$4.81$5.12$4.94
Q1 20173$4.70$5.28$5.00
Q2 20173$5.14$5.28$5.19
Q3 20173$4.94$5.60$5.25
Q4 20174$4.94$5.79$5.26
(Data provided by Zacks Investment Research)


Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Biogen (NASDAQ:BIIB)
Insider Ownership Percentage: 0.32%
Institutional Ownership Percentage: 86.97%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.50View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.28View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.00View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.00View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Biogen (NASDAQ:BIIB)
News IconEarnings Clues on Biogen Inc. (BIIB), Humana Inc. (HUM) Analyst's Predictions - StockNewsJournal (NASDAQ:BIIB) - February 23 at 3:21 PM logoHere's Why Celgene's Latest Drug Is So Exciting (NASDAQ:BIIB) - February 23 at 3:21 PM
News IconNews Impact Score Of Biogen Idec Inc. (NASDAQ:BIIB) At 73 - Stock Observer (NASDAQ:BIIB) - February 22 at 3:56 PM
News IconBuy, Sell or Hold? Analysts Approach: Norfolk Southern Corporation (NSC), Biogen Inc. (BIIB)? - The USA Commerce (NASDAQ:BIIB) - February 22 at 3:56 PM
News IconTop Gainers of the Day: Biogen Inc. (NASDAQ:BIIB) from Biotechnology (NASDAQ:BIIB) - February 22 at 11:56 AM logo​Top pharma lobbyist casts Biogen as the anti-Shkreli during drug price Q&A (NASDAQ:BIIB) - February 21 at 3:24 PM
News IconLookout for Price Target? Biogen Inc (BIIB), The Progressive Corp. (PGR) - StockNewsJournal (NASDAQ:BIIB) - February 21 at 10:41 AM logoDid Biogen Inc. Shoot Itself in the Foot? (NASDAQ:BIIB) - February 21 at 9:15 AM logoCelgene MS Drug Reports Positive Phase 3 Data (CELG) (NASDAQ:BIIB) - February 20 at 3:40 PM logoNordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment (NASDAQ:BIIB) - February 20 at 10:44 AM logoCelgene MS Drug Reports Positive Phase 3 Data (NASDAQ:BIIB) - February 20 at 10:44 AM logoTesaro sees a $5B market opportunity for its cancer drug (NASDAQ:BIIB) - February 17 at 6:13 PM logo​Shkreli defends drug prices, spars with protesters at heated UMass Boston event (NASDAQ:BIIB) - February 17 at 6:13 PM
News IconEquity Perception: Analyst's Indicator Review for Biogen Inc. (BIIB), Baxter International Inc. (BAX) - The USA Commerce (NASDAQ:BIIB) - February 16 at 3:58 PM logoAlzheimer's Market Suffers Yet Another Blow with Merck Drug Setback (NASDAQ:BIIB) - February 16 at 3:58 PM logoA $5B drug for a Massachusetts biotech? Tesaro thinks it has a shot (NASDAQ:BIIB) - February 16 at 3:58 PM logoBioverativ's hemophilia hopes (NASDAQ:BIIB) - February 16 at 5:31 AM logoMerck Halts Late-Stage Alzheimer’s Drug Trial (NASDAQ:BIIB) - February 16 at 5:31 AM logoMerck's Alzheimer's Drug Fails; Are Biogen, Roche, AstraZeneca Next? (NASDAQ:BIIB) - February 16 at 5:31 AM logoBiogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference (NASDAQ:BIIB) - February 16 at 5:31 AM logoAnother Potential Alzheimer's Disease Treatment Bites the Dust: What's Next? (NASDAQ:BIIB) - February 16 at 5:31 AM
News IconThe Leerink Swann Equities Analysts Boost Earnings Estimates for Biogen Inc. (BIIB) (NASDAQ:BIIB) - February 15 at 2:32 AM
News IconStock Price of Biogen Inc. (BIIB) Increases 3.81% (NASDAQ:BIIB) - February 15 at 2:32 AM
News IconBainco International Investors Has $6138000 Stake in Biogen Inc. (BIIB) (NASDAQ:BIIB) - February 14 at 9:31 PM
News IconQuantitative Systematic Strategies LLC Increases Position in Biogen Inc. (BIIB) (NASDAQ:BIIB) - February 14 at 9:31 PM logoBiogen’s Spinraza Hits Insurance Hurdles (BIIB) (NASDAQ:BIIB) - February 13 at 4:25 PM logoRegeneron: It's All Riding On Dupixent (NASDAQ:BIIB) - February 13 at 4:25 PM
News IconThe Biogen Inc. (BIIB) Stock Rating Reaffirmed by Cantor Fitzgerald (NASDAQ:BIIB) - February 11 at 8:59 PM
News IconWhy Analysts put forward these two stocks: Workday, Inc. (WDAY), Biogen Inc. (BIIB) - The USA Commerce (NASDAQ:BIIB) - February 10 at 8:26 PM
News IconForward Earnings Estimate of Biogen Inc.(BIIB) - Highland Mirror (NASDAQ:BIIB) - February 10 at 3:23 PM logoBiotech ETFs Powered by Q4 Earnings (NASDAQ:BIIB) - February 10 at 3:23 PM logoHow Biogen Inc (BIIB) Stock Could Gain Another 25% - (NASDAQ:BIIB) - February 9 at 9:07 PM logoHumana to limit coverage of pricy Biogen drug (NASDAQ:BIIB) - February 9 at 4:04 PM logoWhat's Behind Bioverativ's Spin-Out, and Should You Buy? (NASDAQ:BIIB) - February 8 at 10:05 AM logoBiogen's Slow Rebound Prompts A Vetr Downgrade (NASDAQ:BIIB) - February 7 at 9:54 PM
News IconAnalyst Activity - Robert W. Baird Reiterates Neutral on Biogen (NASDAQ:BIIB) (NASDAQ:BIIB) - February 7 at 4:53 PM
News IconSchroder Investment Management Group Boosts Stake in Biogen Inc. (BIIB) (NASDAQ:BIIB) - February 7 at 4:53 PM
News IconJackson Park Capital Cuts Position in Biogen Inc (BIIB) by $2411988 (NASDAQ:BIIB) - February 7 at 4:53 PM
News IconThe Biogen Inc. (BIIB) Shares Sold by Oppenheimer & Co. Inc (NASDAQ:BIIB) - February 7 at 4:53 PM
News IconBiogen Inc (BIIB) is Upgraded by Citigroup to " Buy" (NASDAQ:BIIB) - February 7 at 4:53 PM logoBiogen upgraded by Citigroup (NASDAQ:BIIB) - February 7 at 4:53 PM logoIn an Ironic Twist, Generics Take Aim at Teva Pharmaceutical (NASDAQ:BIIB) - February 7 at 4:53 PM logoBIOGEN INC. Financials (NASDAQ:BIIB) - February 7 at 4:53 PM logoBiogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:BIIB) - February 7 at 4:53 PM logoCaterpillar, Biogen, CSX, Big-Box Stores In Analyst Crosshairs (NASDAQ:BIIB) - February 7 at 4:53 PM
News IconLeading stocks in today’s market: Biogen Inc. (NASDAQ:BIIB) (NASDAQ:BIIB) - February 4 at 3:59 PM
News IconBiogen Inc. (BIIB) stock slips, "Buy" rating reaffirmed by RBC Capital Markets Analysts - BNB Daily (blog) (NASDAQ:BIIB) - February 3 at 9:06 PM logoFeds Probe Biogen Over Drug Prices, Rebates (BIIB) - Investopedia (NASDAQ:BIIB) - February 3 at 9:06 PM logoBiogen Inc (BIIB) Stock Needs a Biotech Bounceback - (NASDAQ:BIIB) - February 3 at 9:06 PM logoBiogen Faces Federal Probes for Drug Prices, Rebates (NASDAQ:BIIB) - February 3 at 9:06 PM


What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Where is Biogen's stock going? Where will Biogen's stock price be in 2017?

22 equities research analysts have issued twelve-month target prices for Biogen's shares. Their predictions range from $282.00 to $386.00. On average, they expect Biogen's share price to reach $332.53 in the next twelve months.

When will Biogen announce their earnings?

Biogen is scheduled to release their next quarterly earnings announcement on Wednesday, April, 19th 2017.

What are analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:

  • Jefferies Group LLC analysts commented, "This morning BIIB announced a settlement with FWP around Tecfidera IP. While we believe Street expectations were generally balanced going into the 3/17 decision (and we had assumed 50/50 prob. BIIB would be successful), commercial and some IPR risk remains, and recent focus has been more on Spinraza launch and Alzheimer’s, the terms look reasonable to us and help reduce an overhang." (1/18/2017)

  • Cantor Fitzgerald analysts commented, "Date and time of first dissemination: January 06, 2017, 09:14 ET Date and time of production: January 06, 2017, 09:14 ET Target Price / Valuation Methodology: Regeneron Pharmaceuticals – REGN Our $450 price target for Regeneron shares is based on a discounted cash flow (DCF) valuation. Risks to achieving Target Price / Valuation: Regeneron Pharmaceuticals – REGN Regeneron’s revenues and/or EPS may fall below our estimates, resulting in downside to our target price. Specifically, US Eylea revenues from diabetic macular edema may be lower than expected due to competition from laser procedures, and a very short dosing period for Eylea." (1/6/2017)

  • Cowen and Company analysts commented, "Third party sources indicate Spinraza has been priced at a WAC of $125K/injection." (12/30/2016)

  • According to Zacks Investment Research, "Biogen’s multiple sclerosis (MS) franchise should continue driving the top-line while new products should do well. Cost cutting efforts should help the company achieve its guidance. Biogen also has some pipeline events lined up and the company continues to work on strengthening its product portfolio. Moreover, the upcoming spin-off of the hemophilia business will allow Biogen to focus on the neurology segment, which is its key area of expertise. However, Biogen does have some challenges in store. Although the company holds a strong position in the MS market, the emergence of additional PML cases for Tecfidera would weigh heavily on the stock as would pipeline setbacks. Biogen’s interferon products are also under pressure with patients continuing to shift to oral therapies. The investigation into the company’s sales and promotion practices is also concerning." (8/12/2016)

  • Credit Suisse Group analysts commented, "We continue to think long term the base business faces headwinds, but in the near term we think products are defending better through a mix of steadier volumes than expected and price increases. Coupled with strong expense management we think Biogen is positioned well on 2016 earnings and we are forecasting a top and bottom line beat for the full year 2016." (7/22/2016)

Who owns Biogen stock?

Biogen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (4.33%), FMR LLC (3.80%), Sands Capital Management LLC (1.19%), Viking Global Investors LP (0.89%), Franklin Resources Inc. (0.83%) and Orbimed Advisors LLC (0.59%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Caroline Dorsa, Douglas E Williams, Eric K Rowinsky, George A Scangos, John Cox, Robert W Pangia and Stelios Papadopoulos.

Who sold Biogen stock? Who is selling Biogen stock?

Biogen's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Viking Global Investors LP, Sands Capital Management LLC, Tudor Investment Corp Et Al, Franklin Resources Inc., Numeric Investors LLC, AMF Pensionsforsakring AB and Orbimed Advisors LLC. Company insiders that have sold Biogen stock in the last year include Adam Koppel, Adriana Karaboutis, Alfred Sandrock, Caroline Dorsa, George A Scangos and Robert W Pangia.

Who bought Biogen stock? Who is buying Biogen stock?

Biogen's stock was bought by a variety of institutional investors in the last quarter, including DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Renaissance Technologies LLC, Discovery Capital Management LLC CT, Sarissa Capital Management LP, Asset Management One Co. Ltd., State Street Corp, Russell Investments Group Ltd. and Fred Alger Management Inc.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Stelios Papadopoulos.

How do I buy Biogen stock?

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Biogen stock cost?

One share of Biogen stock can currently be purchased for approximately $287.63.

Biogen (NASDAQ:BIIB) Chart for Thursday, February, 23, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Earnings History Chart

Earnings by Quarter for Biogen (NASDAQ:BIIB)

Dividend History Chart

Dividend Payments by Quarter for Biogen (NASDAQ:BIIB)

Last Updated on 2/23/2017 by Staff